#United States #Biopharmaceutical #Lehi, Utah #Halia Therapeutics #Inflammasome

Halia Therapeutics Set to Participate in Major Virtual Forum

Halia Therapeutics, Inc., based in Lehi, Utah, is preparing to showcase its innovative solutions at the upcoming 6th Annual Needham Private Biotech & MedTech Company Virtual 1x1 Forum, scheduled for October 13-14, 2026. This forum serves as a platform for leading biopharmaceutical companies to present their latest developments and engage with investors.

As a clinical-stage biopharmaceutical firm, Halia focuses on creating first-in-class therapies that target inflammasome-driven disease biology, which is crucial in addressing complex health challenges. Specifically, their flagship product, ofirnoflast, is positioned to treat lower-risk Myelodysplastic Syndromes (MDS) and other related hematologic conditions influenced by NLRP3 inflammasome activity. This focus reflects Halia's commitment to tackling significant unmet healthcare needs through innovative therapeutics.

The annual Needham forum brings together a diverse group of investors, CEOs, and innovators in biotech and MedTech industries, fostering an environment conducive to networking and potential collaborations. Participation in such events is vital for companies like Halia that seek to expand their reach while disseminating critical information about their products and technological advancements.

Halia's approach is rooted in human genetic resilience and precision medicine, which ensures that their therapies are tailored to the unique biological processes underlying various diseases. This perspective not only enhances the efficacy of their treatments but also positions Halia as a thought leader in biopharmaceutical research.

The inclusion of Halia Therapeutics in this high-profile event underscores the company’s ongoing progress and strategic importance in the biopharmaceutical landscape. The team is eager to share insights into their pioneering research and highlight their broader pipeline, which is dedicated to providing solutions for inflammation-driven diseases.

The company's commitment to innovation is reflected in its several initiatives aimed at educating and informing stakeholders about their specific therapeutic developments. By facilitating direct conversations with investors during the forum, Halia intends to discuss its strategic direction and how it plans to utilize its advanced therapies to propel the future of medical treatment.

About Halia Therapeutics

As a clinical-stage biotechnology company, Halia Therapeutics specializes in developing therapies that directly address the underlying mechanisms of disease, particularly those driven by inflammasome biology. Their lead program, ofirnoflast, is showing promise in treating lower-risk MDS and in advancing the understanding of inflammation-related pathologies. For more detailed information on their research and development efforts, interested parties can visit their official website at www.haliatx.com.

Participating in the Needham forum represents a call to arms for heightened awareness in the biotech field, enabling Halia to showcase the fruits of its labor and to attract potential investment for future research endeavors. The forum serves as a pivotal touchpoint for companies showcasing innovations in biopharmaceutical sciences while contributing to ongoing education in the sector.

As we approach the date of this important event, the community is eager to see how Halia’s contributions will impact the landscape of therapeutic development. With a focus on precision medicine and a promise of innovative solutions, Halia Therapeutics is poised to play a significant role in the future of healthcare.